A biologic that works locally, without systemic effects, changes the calculation entirely.
In the quiet architecture of human sight, a small protein engineered to block two pathways of inflammation at once may soon offer working-age adults something steroids never could — a targeted reprieve from preventable blindness. Kodiak Sciences is presenting clinical findings for KSI-101 at major ophthalmology gatherings this May, with data from both American and Asian patients converging on the same hopeful result: that macular edema born of inflammation can be met with precision rather than blunt force. The drug has not yet crossed the threshold of approval, but Phase 3 trials are enrolling, and the horizon of 2026 carries the weight of a condition that has, until now, offered patients no locally administered biologic option.
- Ocular inflammatory disease quietly strips central vision from working-age adults, and the only widely available treatment — steroids — carries its own risk of permanent eye damage with prolonged use.
- KSI-101 disrupts this impasse by simultaneously blocking two inflammatory drivers, IL-6 and VEGF, a dual-target approach that no approved intravitreal biologic currently attempts for this indication.
- More than half of patients in both U.S. and Taiwanese cohorts gained at least 15 letters of vision within 24 weeks, and retinal fluid resolved in over 90 percent of American patients by week eight — numbers that held across different underlying causes of inflammation.
- The alignment between geographically and ethnically distinct patient populations strengthens the case for global applicability, a critical signal as the company prepares Phase 3 trials designed to support FDA approval.
- PEAK and PINNACLE, the two pivotal studies now recruiting, are expected to deliver topline results by late 2026 — a timeline that places a potential first-of-its-kind biologic treatment within reach for a population that has long had nowhere else to turn.
Kodiak Sciences is advancing a drug candidate that could fundamentally change how physicians approach a form of retinal inflammation responsible for preventable blindness in working-age adults. This week, the company announced plans to present clinical data for KSI-101 at two major ophthalmology conferences in May, including results from a Taiwanese patient cohort that closely echo findings from earlier American trials.
The condition KSI-101 targets — macular edema secondary to inflammation — causes fluid to accumulate in the macula, the retinal region responsible for sharp central vision. It affects roughly one in three people with ocular inflammatory disease, and steroids, the current standard of care, carry serious risks with long-term use. No approved biologic delivered directly into the eye exists for this indication.
The drug's mechanism sets it apart: as a bispecific protein, it blocks both interleukin-6 and vascular endothelial growth factor simultaneously. In the Phase 1b APEX study, more than half of U.S. patients gained at least 15 letters on the vision chart within 24 weeks, and over 90 percent achieved complete fluid resolution by week eight. The Taiwanese cohort produced strikingly similar outcomes — 58 percent reached the same vision threshold, mean improvement reached 17.8 letters, and retinal swelling dropped below clinical significance after a single injection and remained stable throughout follow-up.
Chief Medical Officer Pablo Velazquez-Martin described the cross-population consistency as meaningful evidence that the drug's benefit extends across diverse patients regardless of the underlying cause or severity of their inflammation. Kodiak will also present preclinical data on two additional bispecific candidates and updates on its ABCD drug-delivery platform at the conferences.
The company is now enrolling patients in two Phase 3 studies, PEAK and PINNACLE, designed to support a biologics license application to the FDA. Topline results are expected in the fourth quarter of 2026. If approved, KSI-101 would become the first locally administered biologic for a disease that currently leaves patients choosing between vision loss and the compounding harms of systemic steroid therapy.
Kodiak Sciences is moving forward with a drug candidate that could reshape how doctors treat a form of eye inflammation that causes preventable blindness in working-age adults. The company announced this week that it will present clinical results for KSI-101 at two major ophthalmology conferences in May, including new data from patients in Asia that mirrors what researchers saw in earlier U.S. trials.
The drug targets macular edema secondary to inflammation—a condition where fluid accumulates in the macula, the part of the retina responsible for sharp central vision. It affects roughly one in three people with ocular inflammatory disease, and it remains the leading cause of vision loss in that population. Currently, steroids are the standard treatment, but they carry significant risks with long-term use, including permanent damage to the eye. There are no approved biologic drugs administered directly into the eye for this indication.
KSI-101 works differently. It is a bispecific protein, meaning it simultaneously blocks two inflammatory pathways—interleukin-6 and vascular endothelial growth factor—rather than targeting just one. In the Phase 1b APEX study conducted in the United States, the drug produced what the company describes as rapid and meaningful improvements. More than half of patients gained at least 15 letters on the vision chart within 24 weeks. Over 90 percent achieved complete resolution of fluid in the retina by week eight. The drug was well tolerated.
What matters most for the company's next steps is that these results held up in a separate cohort of patients treated at tertiary uveitis centers in Taiwan. Fifty-eight percent of Asian patients achieved the same 15-letter vision gain. Mean vision improvement reached 17.8 letters at week 24. Central retinal thickness—a measure of swelling—dropped below 325 micrometers after a single injection and stayed dry throughout follow-up. The improvements occurred across different underlying causes of inflammation, suggesting the drug's benefit is not limited to one disease type.
Pablo Velazquez-Martin, the company's chief medical officer, called the consistency between the U.S. and Asian results significant. "These findings add to the growing body of evidence supporting KSI-101 in MESI and provide early support for its applicability across diverse patient populations globally, irrespective of the underlying cause of the inflammation and the severity of the disease," he said in a statement.
The data will be presented at the American Uveitis Society meeting in Aurora, Colorado on May 2, and at the Association for Research in Vision and Ophthalmology conference in Denver from May 3 to 7. Kodiak will also present preclinical work on two additional bispecific candidates—KSI-102 and KSI-103—designed to address other inflammatory eye diseases, as well as updates on its ABCD platform, a drug-delivery system designed to pack more therapeutic payload into a single injection.
The company is now advancing KSI-101 into two Phase 3 studies called PEAK and PINNACLE, which are actively recruiting patients. These trials are designed to support a biologics license application to the FDA. Topline results are expected to begin arriving in the fourth quarter of 2026. If approved, KSI-101 would offer the first locally administered biologic option for a condition that currently forces patients to choose between vision loss and the long-term complications of systemic steroids.
Notable Quotes
These findings add to the growing body of evidence supporting KSI-101 in MESI and provide early support for its applicability across diverse patient populations globally, irrespective of the underlying cause of the inflammation and the severity of the disease.— Pablo Velazquez-Martin, Chief Medical Officer, Kodiak Sciences
The Hearth Conversation Another angle on the story
Why does it matter that the Asian results matched the U.S. results so closely?
Because it suggests the drug works the same way in different populations—different genetic backgrounds, different disease causes, different healthcare systems. That's what regulators want to see before they approve something globally. It's not guaranteed.
What makes this a bispecific drug different from what's already out there?
Most anti-inflammatory drugs target one pathway. This one hits two at once—IL-6 and VEGF. The thinking is that inflammation in the eye involves both of these, and blocking just one leaves the other still driving damage. The preclinical work suggests that hitting both simultaneously works better.
The source mentions steroids as the current standard. Why are they problematic?
They work, but with long-term use they cause cataracts, glaucoma, infections—permanent damage. You're trading one problem for another. A biologic that works locally in the eye, without systemic effects, changes that calculation entirely.
What's the timeline here?
Phase 3 data starts coming in late this year. If it's positive, they file for FDA approval. If approved, it could be available to patients in 2027 or 2028. But that's all conditional on the larger trials working.
Is there any reason to think they might not?
Phase 1b results don't always predict Phase 3 results. Larger trials can reveal safety signals or efficacy that doesn't hold up. The company is betting it will, but that's always a bet.
How many people could this affect?
Ocular inflammatory disease is the fourth leading cause of vision loss in working-age adults. One-third develop macular edema. That's a significant population with no good options right now.